UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d)

of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 1012, 2026

IMAGENEBIO, INC.

(Exact name of registrant as specified in its charter)

Delaware

001-40287

81-1697316

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(I.R.S. Employer

Identification No.)


12526 High Bluff Drive, Suite 345
San Diego, California		92130
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (858) 345-6265

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading

Symbol(s)

Name of each exchange

on which registered

Common Stock, $0.001 par value

IMA

The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 25.02 ~~Results~~Departure of ~~Operations~~Directors ~~and~~or ~~Financial~~Certain ~~Condition~~Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On March 1012, 2026, ImageneBio, Inc. (the “Company”) ~~announced~~and ~~its~~Erin ~~financial~~Butler, ~~results~~the ~~for~~Company’s ~~the~~Senior ~~quarter~~Vice President, Finance & Administration and ~~fiscal~~Principal ~~year~~Accounting ~~ended~~Officer, ~~December~~agreed to a mutual separation effective March 3120, ~~2025~~2026 (the “Butler Separation Date”). AEffective ~~copy~~as of the ~~press~~Butler ~~release~~Separation isDate, ~~attached~~Ms. Butler ~~hereto~~will no longer serve as ~~Exhibit~~the 99Company’s Principal Accounting Officer.1.

The ~~information~~Company inexpects ~~this~~to ~~Item~~enter ~~2.02,~~into ~~including~~a ~~the~~separation ~~attached~~agreement ~~Exhibit 99.1, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended~~ (the “~~Exchange~~Separation ~~Act~~Agreement”), orwith ~~otherwise~~Ms. Butler, ~~subject~~pursuant to ~~the~~which ~~liabilities~~Ms. Butler ofwill ~~that~~receive ~~Section,~~the ~~nor~~severance ~~shall~~benefits itset beforth ~~deemed incorporated by reference~~ in ~~any~~her ~~filing~~Severance ~~made~~Rights byAgreement, ~~the~~dated ~~Company~~October 21, ~~under~~2024 ~~the~~and ~~Securities~~filed ~~Act of 1933,~~ as ~~amended,~~Exhibit or10.16 to the ~~Exchange~~Current ~~Act,~~Report ~~except~~on asForm ~~shall~~8-K befiled ~~expressly~~with ~~set~~the ~~forth~~U.S. bySecurities ~~specific~~and ~~reference~~Exchange inCommission ~~such~~on aJuly 29, ~~filing~~2025.

~~Item~~The ~~9.01~~Company’s ~~Financial~~board ~~Statements~~of ~~and~~directors ~~Exhibits~~has, effective as of the Butler Separation Date, appointed Bob Lally, our Senior Vice President, Finance & Operations, as the Company’s Principal Accounting Officer.

~~(d)~~Bob ~~Exhibits~~Lally, age 63, has served as our Senior Vice President, Finance & Operations since July 2025. Previously, Mr. Lally served as Senior Vice President, Finance & Operations at our predecessor, Ikena Oncology, Inc. from December 2022 to July 2025. Mr. Lally served in various roles of increasing responsibility at Prevail Therapeutics Inc. where he served as Vice President, Finance from February 2019 through March 2021 and as Chief Operating Officer from March 2021 through June 2022. Prior to that, Mr. Lally served as Executive Director, Finance and Controller at Arsanis, Inc. from May 2016 through March 2019. Mr. Lally holds a B.S. in finance from the University of Massachusetts, Lowell.

Exhibit Number		Description
99.1		Press Release dated March 10, 2026.
104		Cover Page Interactive Data File (embedded with the Inline XBRL document).

Mr. Lally did not enter into any material plan, contract or arrangement with the Company in connection with his appointment as the Company’s principal accounting officer.

There are no family relationships between Mr. Lally and any of the Company’s current or former directors or executive officers. Mr. Lally is not a party to any transaction that would require disclosure under Item 404(a) of Regulation S-K promulgated under the Securities Act of 1933, as amended.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

IMAGENEBIO, INC.

Date: March 10, 2026

/s/ Kristin Yarema

Date: March 17, 2026

/s/ Kristin Yarema

Kristin Yarema, Ph.D.

Chief Executive Officer

Filing Compare · ImageneBio, Inc.